Drugs

Article	Citations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	449
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	441
Bimekizumab for the Treatment of Psoriasis	321
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	316
Targeting DNA Damage Response Deficiency in Thoracic Cancers	227
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	190
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	173
Aprocitentan: First Approval	158
Eftrenonacog Alfa: A Review in Haemophilia B	137
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	134
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	127
Epcoritamab: First Approval	126
Spesolimab for the Treatment of Generalized Pustular Psoriasis	121
Teclistamab: First Approval	117
Vorasidenib: First Approval	116
New Therapies on the Horizon for Primary Biliary Cholangitis	111
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	108
Senaparib: First Approval	107
Upacicalcet: First Approval	106
Cosibelimab: First Approval	106
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	104
Repotrectinib: First Approval	103
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	96
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	96
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	94

Olipudase Alfa: First Approval	93
Ivarmacitinib Sulfate: First Approval	92
Atogepant: First Approval	92
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	92
Drugs in Development to Manage Acute Pain	90
Lenacapavir: First Approval	86
Danicopan: First Approval	83
Acoltremon: First Approval	82
Androgenetic Alopecia: Therapy Update	82
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	82
Finerenone: First Approval	82
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	81
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	80
Cancer Pain Treatment Strategies in Patients with Cancer	77
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	76
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	75
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	75
Olverembatinib: First Approval	73
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	73
Mosunetuzumab: First Approval	73
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	72
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	72
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	72
Correction to: Tapinarof Cream 1%: First Approval	70
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	70
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	68
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	67
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	67
Correction to: Prevention and Treatment of Monkeypox	66
Dorzagliatin: First Approval	65
The Place of Cannabinoids in the Treatment of Gynecological Pain	65
Tovorafenib: First Approval	65
Sunvozertinib: First Approval	64
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	64
Pozelimab: First Approval	62
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	60
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	59
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	59
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	57
Correction to: Concizumab: First Approval	55
Birch Bark Extract: A Review in Epidermolysis Bullosa	55
Tirzepatide: A Review in Type 2 Diabetes	54
Gepirone Extended-Release: First Approval	54
Asciminib: First Approval	54
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	54
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	54
Ozoralizumab: First Approval	54
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	53
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	53
Correction to: Remdesivir: A Review in COVID-19	53

Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	52
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	51
Aumolertinib: A Review in Non-Small Cell Lung Cancer	50
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	50
Catumaxomab: First Approval	50
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	50
Disitamab Vedotin: First Approval	50
Givinostat: First Approval	49
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	49
Correction to: Efmoroctocog Alfa: A Review in Haemophilia A	48
Correction to: Sotorasib: First Approval	48
Correction: Teprotumumab: A Review in Thyroid Eye Disease	47
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	46
Ensitrelvir Fumaric Acid: First Approval	46
Fezolinetant: First Approval	46
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	46
Futibatinib: First Approval	46
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	43
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	43
Avacincaptad Pegol: First Approval	43
Zastaprazan: First Approval	42
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	42
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	42
Tisotumab Vedotin: First Approval	42
Eye Involvement and Management in Inherited Epidermolysis Bullosa	41
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	41
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	41
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	41
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	40
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	40
Correction: Iptacopan: First Approval	38
Beremagene Geperpavec: First Approval	38
Gastrointestinal Dysfunction in Parkinson’s Disease	38
Lotilaner Ophthalmic Solution 0.25%: First Approval	38
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	38
Imeglimin Hydrochloride: First Approval	36
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	36
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	36
Savolitinib: First Approval	36
Imetelstat: First Approval	36
Tebentafusp: First Approval	35
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	35
Acknowledgement to Referees	34
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	34
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	34
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	34
Crinecerfont: First Approval	33
Avatrombopag: A Review in Thrombocytopenia	33
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	33
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	33
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	32
Nogapendekin alfa Inbakicept: First Approval	32
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	32
Revumenib: First Approval	32
Mavorixafor: First Approval	31
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	31
Retifanlimab: First Approval	31
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	31
Correction to: Abrocitinib: First Approval	30
Donafenib: First Approval	30
Correction to: Sparsentan: First Approval	30
Diagnosis and Treatment of AL Amyloidosis	30
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	30
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis	29
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	29
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	28
Correction: Zastaprazan: First Approval	28
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	28
Keverprazan Hydrochloride: First Approval	28
Correction to: Spesolimab: First Approval	27
Ravulizumab: A Review in Generalised Myasthenia Gravis	27
Zolbetuximab: First Approval	27
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	27
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	27
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	27
Methadone for Cancer Pain Management in Children: A Review of Literature	27
Remdesivir: A Review in COVID-19	26
Daridorexant: First Approval	26
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	26
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	26

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	26
Antibacterials with Novel Chemical Scaffolds in Clinical Development	26
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	26
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	25
Gefapixant: First Approval	25
Regdanvimab: First Approval	25
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases	25
Molnupiravir: First Approval	25
Spesolimab: First Approval	25
Marstacimab: First Approval	25
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old	25
Elranatamab: First Approval	25
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	25